Skip to main content
. 2022 May 18;23(10):5675. doi: 10.3390/ijms23105675

Figure 3.

Figure 3

Empagliflozin reduces white adipocyte size and circulating triglycerides in male TallyHo mice. Male and Female TallyHo (squares), SWR/J (triangles), and C57BL6J (circles) were fed a high milk-fat diet in the absence (filled symbols) or presence (open symbols) of 10 mg/kg BW Empagliflozin. The nuchal white fat (WAT) was then isolated and subjected to H&E histological analysis (A,E). (B,F) Quantification of adipocyte diameter, (C,G) circulating triglycerides in male (B,C) and female (F,G) mice. (D) Quantification of macrophage infiltration through the presence of crown-like structures (CLS)/field of view (arrows note CLS). In (B,C), Empagliflozin decreased the adipocyte diameter and circulating triglycerides with * p < p = 0.05. In (D), both TallyHo control and Empagliflozin-treated male mice had significantly more CLS compared to the control strains (* p < 0.05 TallyHo control mice vs. C57BL6J and SWR/J; † p < 0.05 TallyHo Empagliflozin vs. C57BL6J and SWR/J). Scale bar = 50 μm.